A presentation to: Meeting name Date

Slides:



Advertisements
Similar presentations
Phacoemulsification with Goniosynechialysis in the Management of Refractory Acute Angle-closure Glaucoma Ghasem Fakhraie*, MD, Mahmoud Jabbarvand, MD,
Advertisements

Will my Glaucoma patient lose vision ?
TARIQ ALASBALI WHICH PATIENTS ARE AT RISK FOR THE PROGRESSION?
A Randomized Trial of Peribulbar Triamcinolone Acetonide with and without Focal Photocoagulation for Mild Diabetic Macular Edema: A Pilot Study.
Combined cataract surgery and endoscopic cyclophotocoagulation in patients with glaucoma without prior incisional glaucoma surgery Matthew P. Traynor,
PHACO-TRAB VERSUS PHACO ONLY IN EYES WITH ADVANCED OR END-STAGE GLAUCOMA WITH CONTROLLED INTRAOCULAR PRESSURE AND VISUALLY SIGNIFICANT CATARACT Liaska.
Glaucoma Care Project Team Members: Geoffrey T. Emerick, M.D. Erin Herlihy, B.S. Marilyn Hauser, M.B.A. Dianna Greening, R.N. Walter M. Jay, M.D Opportunity.
Vaccines for preventing influenza in healthy adults: a Cochrane review Clinical
2012 實證醫學系統課程 第一組 報告 吳敏誠、鍾宜倫、凌久惠 2012/08/07. Acyclovir for treating primary herpetic gingivostomatitis(Review) Cochrane Library 2008, Issue 4.
4/3/2016 U F G Universidade Federal de Goiás C B C O Centro Brasileiro de Cirurgia de Olhos A Prospective, Comparative Study Between Endoscopic Cyclophotocoagulation.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
Simultaneous Cataract and ECP Glaucoma Surgery An opportunity to improve your vision while reducing or completely eliminating your dependence on Glaucoma.
Surgical Outcomes In Children With Primary Childhood Glaucoma
Effectiveness of yoga for hypertension: Systematic review and meta-analysis Marshall Hagins, PT, PhD1, Rebecca States,
The Efficacy and Safety of the Low Intensity Ultrasound Treatment in Patients with Open Angle Glaucoma Hyoung Won Bae, Gong Je Seong, Chan Yun Kim Institute.
Iwona Helemejko, MD 1; D. Robert Iskander, PhD2
Benjamin Kearns, The University of Sheffield
Tulsi Changulani 1,*, Jenny Bo 2, Mei-Ling Cheng 1, Andrew Tatham 1
IOP control and corneal endothelial cell density changes
Table 1: Table 2: Non Therapeutic Angiograms in Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Does not Adversely Affect Patient.
Abstract # Rates of Complications and Required Additional Surgical Interventions after Surgical and Nonsurgical Treatment in Lumbar Spondylosis:
Lasers in Glaucoma: Meta analysis
A presentation to: Meeting name Date
A presentation to: Meeting name Date
Fatimah Al-Ani 1,2,. MD MRCP, Jose Maria Bastida Bermejo3,
A presentation to: Meeting name Date
Protocol U Short-Term Evaluation of Combination Dexamethasone + Ranibizumab vs. Ranibizumab Alone for Persistent Central-Involved DME Following Anti-VEGF.
Glaucoma.
A presentation to: Meeting name Date
A presentation to: Meeting name Date
Randomized Clinical Trial Jeffrey G. Gross, M.D. for the DRCR Network
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
Clinical Cases in Glaucoma Treatment
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
Q&A – studying medicine or health-related topics at university
A presentation to: Meeting name Date
Short-Term Evaluation of Combination
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
Understanding evidence: The big picture
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
A presentation to: Meeting name Date
Understanding evidence: The big picture
A presentation to: Meeting name Date
Ophthalmology Glaucoma
DRCR Retina Network Treatment for Center-Involved DME in Eyes with Good Visual Acuity (Protocol V)
Micropulse Transscleral Cyclophotocoagulation
Presentation transcript:

A presentation to: Meeting name Date Cyclodestructive procedures for non-refractory glaucoma Manuele Michelessi, Amanda K Bicket, Kristina Lindsley Issue 4, 2018 A presentation to: Meeting name Date

Table of Contents 01 Background 02 Types of studies 03 Key results 04 Conclusions 05 Acknowledgements

01: Background Glaucoma is a progressive disease of the optic nerve causing loss of vision. Intraocular pressure (IOP) is the main treatable risk factor for glaucoma. Cyclodestructive procedures (i.e., procedures that destroy the ciliary body epithelium) may reduce IOP. Objective To assess the effectiveness and safety of cyclodestructive procedures for the management of non-refractory glaucoma (i.e., glaucoma in an eye that has not undergone incisional glaucoma surgery).

02: Types of studies Participants One randomized controlled trial (RCT) with 92 participants (92 eyes) with glaucoma Interventions Head-to-head trials of cyclophotocoagulation (CPC) using different types of lasers, delivery methods, parameters, or a combination of these factors

03: Key results “Control of IOP, defined as a decrease in IOP by 20% from baseline value, was achieved in 47% of eyes, at similar rates in the low-energy group and the high-energy groups; the small study size creates uncertainty about the significance of the difference, if any, between energy settings” Relative risk (RR) 1.03, 95% confidence interval (CI) 0.64 to 1.65; 92 eyes “The difference in effect between energy settings based on mean decrease in IOP, if any exists, also was uncertain” Mean difference (MD) -0.50 mmHg, 95% CI -5.79 to 4.79; 79 eyes

03: Key results (continued) “Twenty-three percent of eyes had a decrease in vision. The size of any difference between the low-energy group and the high-energy group was uncertain” RR 1.22, 95% CI 0.54 to 2.76, 79 eyes “The difference in the mean number of glaucoma medications used after cyclophotocoagulation was similar when comparing treatment groups” MD 0.10, 95% CI -0.43 to 0.63, 79 eyes; moderate-certainty evidence “Twenty per cent of eyes were retreated; the estimated effect of energy settings on the need for retreatment was inconclusive” RR 0.76, 95% CI 0.31 to 1.84, 79 eyes, low-certainty evidence “No data for visual field, cost effectiveness, or quality-of-life outcomes were reported by the trial investigators.”

04: Conclusions “There is insufficient evidence to evaluate the relative effectiveness and safety of cyclodestructive procedures for the primary procedural management of non-refractory glaucoma. “ “Overall, the effect of laser treatment on IOP control was modest and the number of eyes experiencing vision loss was limited.” “More research is needed specific to the management of non-refractory glaucoma.”

05: Acknowledgements Cochrane Eyes and Vision US Satellite, funded by the National Eye Institute, National Institutes of Health Cochrane Eyes and Vision Editorial Base, funded by the UK National Health Service Research and Development Programme Manuele Michelessi, Amanda K Bicket, Kristina Lindsley Review citation Michelessi M, Bicket AK, Lindsley K. Cyclodestructive procedures for non- refractory glaucoma. Cochrane Database of Systematic Reviews 2018, Issue 4. Art. No.: CD009313. DOI: 10.1002/14651858.CD009313.pub2.